HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies

Journal of Korean Medical Science

Volumn 19, Issue 3, 2004, Pages 390-396

  Chang, Eundeok ^b   Lee, Anhi ^b   Lee, Eunjung ^b,c   Lee, Hekyung ^b   Shin, Okran ^b   Oh, Sejeong ^a   Kang, Changsuk ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

Author keywords

Breast Neoplasms; Immunohistochemistry; In Situ Hybridization; Protein Array Analysis; Receptor, erbB 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

EID: 3042799948     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.3.390     Document Type: Article

References (37)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
3. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and Topoisomerase IIα in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-8.
4. Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Benard J, Le MG. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast cancer patients. Int J Cancer 2001; 95: 266-70.
5. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-56.
6. Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 2000; 135: 1469-74.
7. Ross JS, Fletcher JA. HER-2/neu (c-erbB-2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112 (Suppl 1): S53-67.
8. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003; 119: 381-7.
9. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivot trials. Oncology 2001; 61 (Suppl 2): 14-21.
10. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER-2/ gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000; 103: 57-75.
11. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol 2003; 119: 472-85.
12. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001; 344: 783-92.
13. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors. A comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 118: 408-17.
14. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 1988; 58: 448-52.
15. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J. Chromogenic in situ hybridization. A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-72.
16. Tubbs R, Skacel M, Pettay J, Powell R, Myles J, Hicks D, Sreenan J, Roche P, Stoler MH, Hainfeld J. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol 2002; 26: 908-13.
17. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 2001; 51: 579-84.
18. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER-2 oncogene in archival human breast carcinoma. Lab Invest 2002; 82: 1007-14.
19. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER-2/neu gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002; 15: 657-65.
20. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
21. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M, Gilks CB. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002; 15: 1374-80.
22. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003; 16: 79-84.
23. van de Vijver M. Emerging technologies for HER 2 testing. Oncology 2002; 63 (Suppl 1): 33-8.
24. Jacobs TW, Bown AM, Yaziji H, Barnes MJ, Shinitt SJ. Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-7.
25. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M. Current perspectives on HER 2 testing: A review of national testing guidelines. Mod Pathol 2003; 16: 173-82.
26. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000; 13: 37-45.
27. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma : a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000; 13: 866-73.
28. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000; 53: 374-81.
29. Lee TJ, Oh HG, Kwon GY, Kim MK, Park ES, Yoo JH. HER-2/neu oncogene amplification by chromogenic in situ hybridization and immunohistochemical expression of Topoisomerase II-α in the breast cancer. Korean J Pathol 2003; 37: 26-34.
30. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002; 15: 1318-25.
31. Dolan J, Curran B, Henry K, Lindley R, Leader M. C-erbB-2 protein expression and survival in breast carcinoma [abstract]. J Pathol 1989; 158: 354A
32. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-9.
33. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 over expressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
34. Roche PC, Ingle JN. Increased HER-2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999; 17: 434.
35. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002; 126: 803-8.
36. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
37. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER-2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003; 16: 937-43.